A Trial of Tisotumab Vedotin in Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

February 6, 2020

Study Completion Date

August 2, 2022

Conditions
Cervical Cancer
Interventions
DRUG

tisotumab vedotin

All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity

Trial Locations (53)

1200

Cliniques universitaires Saint-Luc, Brussels

2100

Rigshospitalet, Copenhagen

3000

UZLeuvenGynaecologische oncologie, Leuven

4000

CHC SAINT Montlegia, Liège

CHU de LIEGE/ Oncologie Médicale, domaine universitaire du Sart Tilman, Liège

5000

CHU UCL Namur site de Sainte Elisabeth, Namur

6000

Grand Hôpital de Charleroi, Charleroi

6800

Centre Hospitalier de l'Ardenne, Libramont

8000

AZ Sint-Jan Brugge-Oostende av, Bruges

9000

Algemeen Ziekenhuis Maria MiddelaresMedical Oncology - IKG, Ghent

Universitair Ziekenhuis Gent, Ghent

Aalborg Universitetshospital, Aalborg

12851

Vseobecna fakultni nemocnice v Praze, Prague

15006

Hospital Teresa Herrera-CHUAC, A Coruña

18081

Nemocnice Na Bulovce, Gynekologicko-porodnicka kl, Prague

19090

Abington Memorial Hospital, Willow Grove

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

22185

Skåne University Hospital, Lund

28027

Clínica Universidad de Navarra (Sede Madrid), Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Edificio dotacional de Oncología, Madrid

29607

Bon Secours Saint Francis Cancer Center, Greenville

30342

University of Gynecologic Oncology, Atlanta

32258

Southern Baptist Hospital of Florida, Inc, Jacksonville

33136

University of Miami Miller School of Medicine, Miami

35294

University of Alabama, Birmingham

40138

Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna

40207

Louisville Oncology, Louisville

43210

The Ohio State University Wexner Medical Center, Hilliard

45147

Kliniken Essen-Mitte, Düsseldorf

45267

University of Cincinnati, Cincinnati

46219

Community Hospital East, Indianapolis

53226

Froedtert & Medical College Clinics, Milwaukee

62500

Fakultni Nemocnice Brno, Brno

73104

Stephenson Cancer Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa

77030

UT Health McGovern Medical School, Houston

77900

Fakultni nemocnice Olomouc Onkologic, Olomouc

80131

Istituto Nazionale Tumori Fondazione G. Pascale, Naples

81377

Klinikum der Universität München, Münich

85016

Arizona Oncology Associate - Biltmore Cancer Center, Phoenix

87102

University of New Mexico Comprehensive Cancer Center (UNMCCC), Albuquerque

89169

Women's Cancer Center of Nevada, Las Vegas

90095

UCLA Dept. of OBGYN, Los Angeles

01105

Baystate Medical Center, Springfield

08103

MD Anderson Cancer Center at Cooper University Hospital, Camden

Unknown

Irst Irccs, Meldola

00168

Policlinico Universitario Agostino Gemelli, UOC Patologia Ostetrica e Ginecologica, Rome

08036

Hospital Clinic Barcelona, Barcelona

08908

Hospital Duran I Reynals ICO Hospitalet, L'Hospitalet de Llobregat

07198

Fundacion Hospital Son Llatzer, Palma de Mallorca

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genmab

INDUSTRY

collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

collaborator

Belgian Gynaecological Oncology Group

OTHER

collaborator

Gynecologic Oncology Group

NETWORK

lead

Seagen Inc.

INDUSTRY

NCT03438396 - A Trial of Tisotumab Vedotin in Cervical Cancer | Biotech Hunter | Biotech Hunter